<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108845</url>
  </required_header>
  <id_info>
    <org_study_id>201807001</org_study_id>
    <nct_id>NCT04108845</nct_id>
  </id_info>
  <brief_title>Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months</brief_title>
  <official_title>A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laishui Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes for Food and Drug Control, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simoon Record Pharma Information Consulting Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety of 15-Valent Pneumococcal Conjugate Vaccine
      in healthy volunteers aged above 3 Months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events in 30 minutes</measure>
    <time_frame>30 minutes after each vaccination</time_frame>
    <description>Occurrence of adverse events in 30 minutes after each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited adverse events during 7 days</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>Occurrence of solicited adverse events during a 7-day follow-up period after each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events during 30 days</measure>
    <time_frame>30 days after each vaccination</time_frame>
    <description>Occurrence of unsolicited adverse events during a 30-day follow-up period after each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAE</measure>
    <time_frame>from enrolling to 6 months after all vaccinations</time_frame>
    <description>Occurrence of serious adverse events (SAE) from enrolling to 6 months after all vaccinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood routine of subjects over 18 years old at the fourth day</measure>
    <time_frame>4 days after vaccination</time_frame>
    <description>Blood routine test results of subjects over 18 years old at the fourth day after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood biochemistry of subjects over 18 years old at the fourth day</measure>
    <time_frame>4 days after vaccination</time_frame>
    <description>Blood biochemistry test results of subjects over 18 years old at the fourth day after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine routine of subjects over 18 years old at the fourth day</measure>
    <time_frame>4 days after vaccination</time_frame>
    <description>Urine routine test results of subjects over 18 years old at the fourth day after vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects ratio of vaccine serotype specific pneumococcal IgG antibody concentration ≥ 0.35 ug/ml or 1.0 ug/ml in 2-month-old and 3-month-old subjects</measure>
    <time_frame>30 days after immunization</time_frame>
    <description>Subjects ratio of vaccine serotype specific pneumococcal IgG antibody concentration ≥ 0.35 ug/ml or 1.0 ug/ml in 2-month-old and 3-month-old subjects on 30 days after immunization with 15-valent pneumococcal polysaccharide conjugate vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC of vaccine serotype specific pneumococcal IgG antibody in 2-month-old and 3-month-old subjects</measure>
    <time_frame>30 days after immunization</time_frame>
    <description>Geometric mean concentration (GMC) of vaccine serotype specific pneumococcal IgG antibody in 2-month-old and 3-month-old subjects on 30 days after immunization with 15-valent pneumococcal polysaccharide conjugate vaccine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received Vaccine: 15-valent pneumococcal Conjugate Vaccine, 0.5 ml/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>15-Valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 months old (at a minimum of 6 weeks old) and above healthy people.

          -  Subject or legal representative who consent and has signed written informed consent.

          -  Subject and parent/guardian who is able to comply with all study procedures and to use
             thermometer, scale and fill in diary card and contact card as required.

          -  Subject who didn't vaccinate 13-valent or 7-valent pneumococcal conjugate vaccine.

          -  Subject who did't immune with any live vaccine within 14 days and inactivated vaccine
             within 7 days before vaccination.

          -  Axillary temperature ≤37.0 ℃.

        Exclusion Criteria:

          -  Subject with a history of a prior bacterial culture of an aggressive disease caused by
             S. pneumoniae.

          -  Subject with any previous history of severe vaccination or drug allergy, occurrence of
             fever ≥ 39.0° related to vaccination of biological products for previous vaccination.

          -  Subject who are allergic to diphtheria toxins.

          -  Children below 1 year old with abnormal labor（dystocia, instrument midwifery), birth
             weight &lt;2500g, asphyxia rescue history, nerve organ damage history, and pathological
             history of yellow plague determined by diagnosis.

          -  History of allergy，eclampsia, epilepsy,brain trauma,encephalopathy and mental disease
             or family disease.

          -  Subject who diagnosis of thrombocytopenia or other history of coagulopathy.

          -  Known severe congenital malformations, developmental disorders; clinically diagnosed
             serious chronic diseases: down's syndrome, diabetes, sickle cell anemia or
             neurological disorders, Guillain Barre syndrome.

          -  Known or suspected to suffer from: severe cardiovascular disease, liver and kidney
             disease, malignant tumor, skin disease, serious respiratory system disease, acute
             infection or chronic disease active period.

          -  Known or suspected to suffer from immunological abnormalities, including
             immunosuppressive therapy (radiotherapy, chemotherapy, corticosteroids, antimetabolic
             drugs, cytotoxicity drugs), HIV infection, etc.

          -  Received blood products or immunoglobulin within 3 months before enrolling (hepatitis
             B immunoglobulin was acceptable), or planned to use it during the clinical trial
             period (before blood samples were collected after immunization).

          -  Subject who plan to participate in or is in any other clinical trial (vaccines, drugs,
             medical devices, etc.).

          -  In pregnancy or lactation or pregnant women.

          -  ≥18-year-old subject with blood routine, blood chemistry or urinalysis laboratory
             collection abnormalities.

          -  Any condition that, in the judgment of investigator, may affect trial assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Du Lin, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laishui Center for Disease Control and Prevention</name>
      <address>
        <city>Laishui</city>
        <state>Hebei</state>
        <zip>074199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Po</last_name>
      <phone>86 18903365570</phone>
      <email>m18903365570@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

